Navigation Links
Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
Date:4/29/2009

SYDNEY, April 29 /PRNewswire/ -- Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, has agreed to provide milestone payments over the next two years to Clinical Genomics to further develop its portfolio of gene-based biomarkers associated with early onset of colorectal cancer. Clinical Genomics was awarded the payments after successfully achieving key research and development goals. Under terms of a worldwide license agreement, Quest Diagnostics has exclusive rights to the biomarkers for use in developing a test as an aid in detecting precancerous and cancerous colorectal tumors in conjunction with other clinical findings. Additional financial terms were not disclosed.

Clinical Genomics, in collaboration with Flinders University (South Australia) and the Australian Government's Commonwealth Scientific and Industrial Research Organization (CSIRO, Australia), has discovered molecular markers that show promise as aids in detection of both colorectal cancer and precancerous adenomas.

"Quest Diagnostics is at the forefront of efforts to develop and offer cancer testing innovations, including gene-based blood tests and fecal immunochemical tests associated with the detection of colorectal cancer," said Lawrence LaPointe, CEO of Clinical Genomics. "We are excited that as the world's leader in cancer diagnostics, Quest Diagnostics appreciates the potential of our proprietary biomarkers to form the basis for a laboratory test that one day may aid the detection of early-stage colorectal cancer."

Colorectal cancer is the second most common cause of cancer related death of both men and women in the United States and Australia. Colorectal cancer is largely treatable when detected in the early stages. Yet, due to low screening rates, fewer than 40 percent of cases are caught early [1].

In 2006, Quest Diagnostics acquired Enterix Inc., manufacturer of the FDA- cleared InSure(R) fecal immunochemical test (FIT) for aiding the detection of colorectal cancer based on stool testing. Quest Diagnostics also made an equity investment in Clinical Genomics, which was formed as a spin off from Enterix's research and development.

[1]American Cancer Society

About Clinical Genomics

Clinical Genomics is a Sydney-based biotechnology company formed in 2006 to exploit the patented and patent-pending gene expression biomarkers of colorectal cancer discovered by its founders and Flinders University in 2001. Clinical Genomics continues to work closely with Flinders University and CSIRO to advance the development of products that will improve the detection and management of this serious disease. Additional information is available at: www.clinicalgenomics.com.


    Contact: (For Clinical Genomics)
    Lawrence LaPointe,
    +61 4 0099 5027,
    larry@clinicalgenomics.com


'/>"/>
SOURCE Clinical Genomics Pty Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
2. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
5. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
6. Clinical Update - Debio 025 in Hepatitis C
7. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
8. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
9. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
10. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
11. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 A ... growth is the emergence of new treatments. Cardax, a ... for osteoarthritis treatment. The therapy is expected to fulfil ... Research UK is conducting studies to develop new treatments ... where the genes involved in osteoarthritis are being investigated, ...
(Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the ...
(Date:5/25/2016)... und GERMANTOWN, Maryland , May ... mit Therawis bedient dringenden ... QIAGEN N.V. (NASDAQ: QGEN ... eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH ... Onkologie eingegangen zu sein. Ein erstes Projekt wird ...
Breaking Medicine Technology:
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... The ... industry, today released ten predictions on the future of wellness, travel, spa and beauty ... top travel, spa and beauty companies to leading economists and researchers - to forecast ...
(Date:5/31/2016)... ... ... The Orthopaedic Research and Education Foundation (OREF) is pleased to announce the following ... term as president in March, succeeding John J. Callaghan, MD, who remains on the ... Kyle, MD, will serve as chair, corporate development, succeeding Thomas P. Schmalzried, MD, in ...
(Date:5/31/2016)... ... ... a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY Town ... leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have combined ... the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, the ...
(Date:5/31/2016)... ... May 31, 2016 , ... To meet a ... the healthcare industry, The University of Scranton is adding a Certificate in Health ... a career in rapidly growing field of healthcare information. , Healthcare organizations ...
(Date:5/30/2016)... ... May 30, 2016 , ... "This plugin ... said Christina Austin - CEO of Pixel Film Studios. , TransPack Volume ... Pro X. Choose from abstract transitions to more simple wipes with blur & ...
Breaking Medicine News(10 mins):